Loading...
XNAS
PLSE
Market cap3.40bUSD
Oct 08, Last price  
49.98USD
1D
1.81%
1Q
90.11%
Jan 2017
668.92%
IPO
1,125.00%
Name

Pulse Biosciences Inc

Chart & performance

D1W1MN
XNAS:PLSE chart
P/E
—
P/S
9,883.15
EPS
—
Div yield, %
—
Shrs. gr., 5y
23.72%
Rev. gr., 5y
%
Revenues
350k
00000001,418,000700,00000350,000
Net income
-73m
L+35.82%
-474,857-2,811,283-9,518,000-25,567,000-37,545,000-45,988,000-49,737,000-63,660,000-58,505,000-42,210,000-53,585,000-72,781,000
CFO
-54m
L+48.92%
-173,143-3,316,768-8,051,000-11,087,000-23,896,000-34,185,000-35,365,000-54,097,000-47,013,000-33,041,000-36,343,000-54,122,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.
URL
https://www.pulsebiosciences.com/
IPO date
May 18, 2016
Employees
61
Domiciled in
US
Incorporated in
US
Legal address
c/o The Corporation Trust Company, Corporation Trust Center, 1209 Orange Street
Wilmington, DE 19801
US
Headquarters
3957 Point Eden Way
Hayward, CA 94545
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT